Sara Tolaney· @stolaney1 · X·· 2 days agoScore90
Body
PANKU-Breast01
HR+ MBC, prior cdk 4/6i, 1-2 prior chemo
Iza-bren vs TPC
~70% 1 prior chemo
PFS 8.2 vs 4.0 mo, HR 0.41 p<0.0001
ORR 40.5% vs 20.2%
DOR 6.9 mo vs 4.2 mo
OS immature
Most tox: heme tox, primary GCSF was not required
@OncoAlert #ESMO26
451 views · 8 likes · 8 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Sara Tolaney · x.com